The finding that GATA1 is able to bind and activate the Bcl-x promoter coupled with the high correlation between GATA1 expression and Bcl-xL transcript levels in primary patient samples offers a potential explanation for why AML patients with high GATA1 expression have been found to have poorer outcomes. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.